Investors & Media International Stem Cell Corporation and The Automation Partnership Enter into Strategic Alliance to Automate Cornea Tissue Production Recent article about ISCO's Cornea Program International Stem Cell and Absorption Systems Confirm Results Showing Stem Cell Derived Corneal Tissue as an Alternative to Animals for Drug Testing International Stem Cell Corporation Engages Leading Immunogeneticists to Advance its Industry-first, Immune-matched Stem Cells International Stem Cell Corporation Provides Strategic Update on Its Skin Care Program International Stem Cell (ISCO) Announces the Signing of a Distribution Agreement with Veritas Corporation, Opening Japanese Markets for Its Lifeline Cell Technology® Brand of Human Cell Culture Products International Stem Cell Corporation Begins Its Second Pre-Clinical Phase of Testing Retinal Pigment Epithelium (RPE) Derived from Human Parthenogenetic Stem Cells for Treatment of Retinal Diseases International Stem Cell Corporation Parthenogenetic Stem Cell Line Shown to Carry the Most Common Immune Genes Matched to the U.S. Population Retains Stem Cell Characteristics over Two Years in Culture, Which is Necessary for Therapeutic Value International Stem Cell Corporation Provides Strategic Update on the Company's Cornea Transplantation Program International Stem Cell Corporation Opens Facility for Development and Production of Clinical-Grade Stem Cell Products 22 23 24 25 26 27 28 29 30 31 32 << < > >>
